{"id":"NCT01233258","sponsor":"Bayer","briefTitle":"A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A","officialTitle":"A Phase II/III, Randomized, Cross-over, Open-label Trial to Demonstrate Superiority of Prophylaxis Over On-demand Therapy in Previously Treated Subjects With Severe Hemophilia A Treated With Plasma Protein-free Recombinant FVIII Formulated With Sucrose (BAY 81-8973)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2010-11-03","resultsPosted":"2014-02-11","lastUpdate":"2016-11-28"},"enrollment":80,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A"],"interventions":[{"type":"BIOLOGICAL","name":"rFVIII (BAY81-8973) on demand","otherNames":[]},{"type":"BIOLOGICAL","name":"rFVIII (BAY81-8973) prophylaxis low-dose","otherNames":[]},{"type":"BIOLOGICAL","name":"rFVIII (BAY81-8973) prophylaxis high-dose","otherNames":[]}],"arms":[{"label":"Arm 1: rFVIII on demand first CS/EP then CS/ADJ","type":"EXPERIMENTAL"},{"label":"Arm 2: rFVIII on demand first CS/ADJ then CS/EP","type":"EXPERIMENTAL"},{"label":"Arm 3: rFVIII prophylaxis low-dose first CS/EP then CS/ADJ","type":"EXPERIMENTAL"},{"label":"Arm 4: rFVIII prophylaxis low-dose first CS/ADJ then CS/EP","type":"EXPERIMENTAL"},{"label":"Arm 5: rFVIII prophylaxis high-dose first CS/EP then CS/ADJ","type":"EXPERIMENTAL"},{"label":"Arm 6: rFVIII prophylaxis high-dose first CS/ADJ then CS/EP","type":"EXPERIMENTAL"}],"summary":"The objective of the trial is to demonstrate that 2-3 times per week prophylaxis therapy with BAY81-8973 is superior to on-demand therapy with BAY81-8973 in patients with severe Hemophilia A. The hypothesis is that prophylaxis will result in fewer bleeds than on-demand treatment.","primaryOutcome":{"measure":"Annualized Number of All Bleeds","timeFrame":"Up to 12 months (6 months per mode of potency assignment according to the randomized cross-over design)","effectByArm":[{"arm":"rFVIII (BAY81-8973) on Demand","deltaMin":57.7,"sd":24.6},{"arm":"rFVIII (BAY81-8973) Prophylaxis Treatment","deltaMin":4.9,"sd":6.8}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":47,"countries":["United States","Argentina","China","Colombia","Czechia","India","Indonesia","Japan","Mexico","Romania","Russia","Serbia","Slovakia","South Africa","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["27002680","26931631","25546368"],"seeAlso":["http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":80},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Influenza","Insomnia"]}}